Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib

OBJECTIVE: Investigate the association between 8-week tumor volume decrease and survival in an independent cohort of EGFR-mutant advanced non-small-cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and assess the rate of their volumetric tumor growth after the volume...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Acad Radiol
Main Authors: Nishino, Mizuki, Dahlberg, Suzanne E., Fulton, Linnea E., Digumarthy, Subba R., Hatabu, Hiroto, Johnson, Bruce E., Sequist, Lecia V.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4744559/
https://ncbi.nlm.nih.gov/pubmed/26776293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.acra.2015.11.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares